Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02063217 · ClinicalTrials.gov registry record · NA
Modulation of CSF Amyloid-beta Concentrations Via Behavioral Sleep Deprivation and Pharmacological Sleep Induction
A NA study of Amyloid-beta, sponsored by Washington University School of Medicine.
- Completed
- Registry status
- NA
- Development phase
- 36
- Enrollment target
- 1
- Study location
NCT02063217 is a NA study of Amyloid-beta that has completed, run by Washington University School of Medicine. The registered enrollment target is 36 participants. The trial reports 1 study location across 1 state.
The verdict
NCT02063217, a NA study of Amyloid-beta, has completed, sponsored by Washington University School of Medicine.
- COMPLETED
- Registry status
- NA
- Development phase
- 36 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to change the concentration of amyloid-beta in human cerebrospinal fluid (CSF) through modulation of the sleep-wake cycle.
Conditions Studied
Interventions
- BEHAVIORAL Sleep deprivation
- DRUG Sodium Oxybate
Study Locations (1)
Missouri
- Washington University Medical School - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2013-12 |
| Est. Completion | 2016-07 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02063217
The ClinicalTrials.gov registry entry for NCT02063217 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Amyloid-beta appearing as the primary indexed condition, and to 2 interventions - of which Sleep deprivation is the first listed.
NCT02063217 reports 1 study location spanning 1 distinct geographic area - top geographies include Missouri.
Frequently Asked Questions
What is clinical trial NCT02063217 about?
NCT02063217 is a clinical study titled "Modulation of CSF Amyloid-beta Concentrations Via Behavioral Sleep Deprivation and Pharmacological Sleep Induction". The purpose of this study is to change the concentration of amyloid-beta in human cerebrospinal fluid (CSF) through modulation of the sleep-wake cycle.
What is the current status of trial NCT02063217?
This trial is currently completed. It is a NA study. The enrollment target is 36 participants. The study started on 2013-12. Estimated completion is 2016-07.
What conditions does trial NCT02063217 study?
This clinical trial studies the following conditions: Amyloid-beta.
What interventions are being tested in trial NCT02063217?
The interventions under investigation include: Sleep deprivation (BEHAVIORAL), Sodium Oxybate (DRUG).
Who is sponsoring clinical trial NCT02063217?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02063217 being conducted?
This trial has 1 study location across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.